Basel, North West Switzerland
Web: Novartis external link
Lieu: Bâle
Lié à:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

Médecine 22.6
Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis -   Despite current treatments about 40% of heart attack sur
Médecine 21.6

AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance -   Filing is supported by a comprehensive clinical progr

Médecine 20.6

RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48 , in two head-to-head pivotal Phase III studies , -   57% and 52% of

Médecine 17.6

Large-scale European patient survey found that 94% of severe allergic asthma patients were unable to fully control their disease - â?

Médecine 20.6

Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden Urgent need to improve management of chronic urticaria (

Médecine 19.6

European Commission approves Sandoz Rixathon â? to treat blood cancers and immunological diseases.

Médecine 15.6

Cosentyx â? is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , - â? Additional data show rapi